ImmuCell

ImmuCell Treasury Stock

The Treasury Stock of ImmuCell (ICCC) as of Nov 15, 2026 is 41.35 M USD. In the previous year, Treasury Stock was 40.78 M USD — a change of 1.40% (higher).

Treasury Stock

41.35 MUSD

YoY

1.40%

Last updated:

Treasury Stock of ImmuCell is 2025 41.35 M USD. Treasury Stock of ImmuCell was 2024 40.78 M USD. It decreases by 1.40% higher compared to the previous year.

The ImmuCell Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2018
22.49 M USD
Jan 1, 2019
30.94 M USD
Jan 1, 2020
31.20 M USD
Jan 1, 2021
35.53 M USD
Jan 1, 2022
35.83 M USD
Jan 1, 2023
36.22 M USD
Jan 1, 2024
40.78 M USD
Jan 1, 2025
41.35 M USD
The ImmuCell Treasury Stock history
YEARTreasury StockYoY
41.35 MUSD+1.40%
40.78 MUSD+12.59%
36.22 MUSD+1.08%
35.83 MUSD+0.84%
35.53 MUSD+13.90%
31.20 MUSD+0.82%
30.94 MUSD+37.58%
22.49 MUSD+2.00%
22.05 MUSD+21.86%
18.09 MUSD+86.55%
9.70 MUSD+1.77%
9.53 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

Treasury Stock of ImmuCell is 41.35 M USD in 2025.

Treasury Stock of ImmuCell changed from 40.78 M USD to 41.35 M USD, representing a 1.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock ImmuCell since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's ImmuCell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ImmuCell

All Key Metrics — ImmuCell